Post-finasteride syndrome, [PDF]
Anais Brasileiros de Dermatologia, 2020 Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects.
Ana Francisca Junqueira Ribeiro Pereira +1 more
doaj +8 more sources
Post-finasteride syndrome: An emerging clinical problem [PDF]
Neurobiology of Stress, 2020 The presence of side effects during pharmacological treatment is unfortunately a quite common problem. In this review, we focused our attention on adverse events related to 5 alpha-reductase (5α-R) inhibitors (i.e., finasteride and dutasteride), approved
Silvia Diviccaro +2 more
doaj +7 more sources
Finasteride Side Effects and Post-Finasteride Syndrome in Male Androgenic Alopecia [PDF]
Journal of Mind and Medical Sciences, 2015 Finasteride is in present a relatively frequent prescribed drug for male androgenic alopecia. The adverse effects reported by some patients seem to be notable, consisting of various (physical, mental/ neurological, sexual, etc.) manifestations which are ...
Manea Mirela +3 more
doaj +8 more sources
Finasteride adverse effects and post-finasteride syndrome; implications for dentists [PDF]
Journal of Mind and Medical Sciences, 2016 Finasteride is a 5α-reductase inhibitor widely used in present in the therapeutic approach of androgenic alopecia. Adverse effects consist in variable sign and symptoms, the most common being represented by mental troubles (reduced feeling of life ...
Stana Paunica +7 more
doaj +8 more sources
Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. [PDF]
Transl Androl Urol, 2022 Finasteride is widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA). Post-finasteride syndrome (PFS) is a spectrum of persistent symptoms reported by some patients after treatment with finasteride for androgenetic alopecia.
Li X +6 more
europepmc +7 more sources
Post-finasteride syndrome: our current knowledge
Вестник урологии, 2020 5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications.
A. A. Galushkin +2 more
doaj +4 more sources
Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? [PDF]
Skin Appendage Disord, 2019 Post-finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat either hair loss or benign prostatic hyperplasia, independent of age, dosage, or indication. By definition, the condition is characterized by sexual dysfunction, somatic symptoms, and psychological disorders that persist after cessation of ...
Trüeb RM +3 more
europepmc +5 more sources
8679 Case: The Sexual, Physical and Psychological Effects of Post-Finasteride Syndrome [PDF]
J Endocr SocAbstract Disclosure: E.M. Lonergan: None. S.M. Maher: None. I. Yaseen: None. D.B. O'Shea: None. Post-finasteride syndrome (PFS) is an increasingly recognised disorder with a myriad of physical and neuropsychiatric symptoms persisting for greater than three months in a small proportion of patients treated with Finasteride ...
Eibhlin Lonergan +3 more
europepmc +4 more sources
Post-Finasteride Syndrome or Pre-Existing Vulnerability? Rethinking Patient Selection. [PDF]
J Cosmet DermatolRivetti N.
europepmc +5 more sources
The postfinasteride syndrome; an overview [PDF]
Journal of Mind and Medical Sciences, 2016 As a 5-α reductase inhibitor, Finasteride has proven effective in ameliorating two conditions documented to be androgen dependent, namely male androgenic alopecia and benign prostatic hyperplasia. Therapeutic results are maintained as long as the drug is
David L. Rowland +9 more
doaj +8 more sources